An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration resistant prostate cancer Meeting Abstract
| Authors: | Rathkopf, D. E.; Saleh, M. N.; Tsai, F. Y. C.; Bilen, M. A.; Rosen, L. S.; Gottardis, M.; Infante, J. R.; Adams, B. J.; Liu, L.; Theuer, C. P.; Freddo, J. L.; Agarwal, N. |
| Abstract Title: | An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration resistant prostate cancer |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Language: | English |
| ACCESSION: | WOS:000487345801574 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.e16542 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: e16542 -- Source: Wos |
